NexImmune Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
50
- Stock Symbol
-
NEXI
- Share Price
-
$0.23
- (As of Friday Closing)
NexImmune General Information
Description
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
Contact Information
Website
www.neximmune.comCorporate Office
- 9119 Gaither Road
- Gaithersburg, MD 20877
- United States
Corporate Office
- 9119 Gaither Road
- Gaithersburg, MD 20877
- United States
NexImmune Stock Performance
As of 06-Dec-2024, NexImmune’s stock price is $0.23. Its current market cap is $321K with 1.39M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.23 | $0.23 | $0.20 - $28.69 | $321K | 1.39M | 3.71K | -$18.50 |
NexImmune Financials Summary
As of 30-Jun-2024, NexImmune has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (669) | (6,047) | (38,362) | 11,456 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (20,179) | (32,018) | (62,176) | (49,178) |
| Net Income | (20,617) | (32,344) | (62,506) | (50,902) |
| Total Assets | 5,861 | 8,594 | 43,060 | 91,032 |
| Total Debt | 0 | 69 | 1,025 | 0 |
NexImmune Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
NexImmune Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
NexImmune Comparisons
Industry
Financing
Details
NexImmune Competitors (62)
One of NexImmune’s 62 competitors is Iovance Biotherapeutics, a Corporation company based in San Carlos, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Iovance Biotherapeutics | Corporation | San Carlos, CA | ||||
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| Cellerant Therapeutics | Venture Capital-Backed | Newark, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA |
NexImmune Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NexImmune Patents
NexImmune Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3118757-A1 | T cell compositions with improved phenotypic properties | Pending | 08-Nov-2018 | ||
| EP-3876979-A4 | T cell compositions with improved phenotypic properties | Pending | 08-Nov-2018 | ||
| EP-3876979-A1 | T cell compositions with improved phenotypic properties | Pending | 08-Nov-2018 | ||
| US-20200188435-A1 | T cell compositions with improved phenotypic properties | Pending | 08-Nov-2018 | ||
| AU-2019375997-A1 | T cell compositions with improved phenotypic properties | Pending | 08-Nov-2018 | A61K35/17 |
NexImmune Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NexImmune ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
40.54 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Pharmaceuticals
Subindustry
of 455
Rank
Percentile
NexImmune FAQs
-
When was NexImmune founded?
NexImmune was founded in 2011.
-
Where is NexImmune headquartered?
NexImmune is headquartered in Gaithersburg, MD.
-
What is the size of NexImmune?
NexImmune has 50 total employees.
-
What industry is NexImmune in?
NexImmune’s primary industry is Biotechnology.
-
Is NexImmune a private or public company?
NexImmune is a Public company.
-
What is NexImmune’s stock symbol?
The ticker symbol for NexImmune is NEXI.
-
What is the current stock price of NexImmune?
As of 06-Dec-2024 the stock price of NexImmune is $0.23.
-
What is the current market cap of NexImmune?
The current market capitalization of NexImmune is $321K.
-
Who are NexImmune’s competitors?
Iovance Biotherapeutics, TScan Therapeutics, Cellerant Therapeutics, Kite Pharma, and Sorrento Therapeutics are some of the 62 competitors of NexImmune.
-
What is NexImmune’s annual earnings per share (EPS)?
NexImmune’s EPS for 12 months was -$18.50.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
